FDA & Regulatory
Tracker
Compounding eligibility, WADA classifications, country-by-country regulations, and safety red flags for research peptides.
Eligible
(6)Sermorelin
ShopSermorelin was previously FDA-approved (Geref) but discontinued commercially. Now available through compounding pharmacies with a valid prescription.
Updated: 2025-12-01
Gonadorelin
NAD+ (Nicotinamide Adenine Dinucleotide)
NAD+ is available through compounding pharmacies and as a supplement (NR/NMN precursors).
Glutathione
Available through compounding pharmacies for SC/IV use under 503A
Updated: 2025-06
L-Carnitine (Injectable)
Available through compounding pharmacies; also FDA-approved as Carnitor
Updated: 2025-06
GHK (Glycyl-Histidyl-Lysine)
Available through compounding pharmacies for topical and injectable use
Updated: 2025-06
Under Review
(2)LL-37
LL-37 compounding eligibility is under FDA review. Status may change based on PCAC recommendations.
Updated: 2025-12-01
Kisspeptin
Removed from Category 2
(2)BPC-157
ShopRemoved from Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility.
Updated: 2026-04-15
Thymosin Beta-4
Previously available through compounding pharmacies; FDA removed from bulk drug substance list
Updated: 2025-06
Ineligible
(100)TB-500
ShopTB-500 is not on the FDA 503A bulk drug substance list for compounding.
Updated: 2025-12-01
Ipamorelin
ShopIpamorelin is not on the FDA 503A bulk drug substance list for compounding.
Updated: 2025-12-01
CJC-1295
ShopCJC-1295 is not on the FDA 503A bulk drug substance list for compounding.
Updated: 2025-12-01
GHK-Cu
ShopGHK-Cu (injectable) is not on the FDA 503A bulk drug substance list for compounding. Topical formulations may be available through compounding pharmacies.
Updated: 2025-12-01
Melanotan II
ShopMelanotan II is not on the FDA 503A bulk drug substance list. Not approved for any human use in any jurisdiction.
Updated: 2025-12-01
AOD-9604
AOD-9604 is not on the FDA 503A bulk drug substance list for compounding. Has FDA GRAS status as a food ingredient only.
Updated: 2025-12-01
MOTS-c
ShopMOTS-c is not on the FDA 503A bulk drug substance list for compounding.
Updated: 2025-12-01
GHRP-6
GHRP-6 is not on the FDA 503A bulk drug substance list for compounding.
Updated: 2025-12-01
GHRP-2
GHRP-2 (pralmorelin) is not on the FDA 503A bulk drug substance list for compounding. Approved as a diagnostic agent in Japan only.
Updated: 2025-12-01
Epithalon
Thymosin Alpha-1
Selank
Semax
Dihexa
DSIP
MK-677
KPV
ShopHexarelin
IGF-1 LR3
FOXO4-DRI
Humanin
PEG-MGF
5-Amino-1MQ
Follistatin 344
Amylin
Endogenous hormone; synthetic analog pramlintide is the approved therapeutic
Updated: 2025-06
Alexamorelin
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Tabimorelin
Discontinued research compound; not eligible for compounding
Updated: 2025-06
MGF
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
IGF-1 DES
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
HGH Fragment 176-191
Research peptide fragment; not eligible for compounding under 503A
Updated: 2025-06
Larazotide
Investigational drug; not eligible for compounding under 503A
Updated: 2025-06
Thymulin
Research peptide; not an FDA-approved drug
Updated: 2025-06
Beta-Defensins
Endogenous antimicrobial peptides; no therapeutic product
Updated: 2025-06
Alpha-Defensins
Endogenous antimicrobial peptides; no therapeutic product
Updated: 2025-06
Lactoferricin
Naturally derived antimicrobial peptide; no FDA-approved formulation
Updated: 2025-06
Melittin
Bee venom-derived peptide; research use only
Updated: 2025-06
Histatin-5
Endogenous salivary peptide; no therapeutic product
Updated: 2025-06
Pexiganan
Investigational antimicrobial peptide; FDA approval denied
Updated: 2025-06
Omiganan
Investigational antimicrobial peptide; not FDA-approved
Updated: 2025-06
Brilacidin
Investigational defensin-mimetic; not FDA-approved
Updated: 2025-06
IM862
Investigational peptide; development discontinued
Updated: 2025-06
Noopept
Research nootropic; not FDA-approved; sold as supplement in some markets
Updated: 2025-06
Pinealon
Research peptide; not FDA-approved
Updated: 2025-06
Cortagen
Research peptide; not FDA-approved
Updated: 2025-06
N-Acetyl Semax Amidate
Research nootropic; not FDA-approved; derivative of Semax
Updated: 2025-06
PE-22-28
Research peptide; not FDA-approved
Updated: 2025-06
Substance P
Endogenous neuropeptide; not an FDA-approved drug product
Updated: 2025-06
Neuropeptide Y
Endogenous neuropeptide; not an FDA-approved drug product
Updated: 2025-06
VIP (Vasoactive Intestinal Peptide)
Endogenous neuropeptide; aviptadil (synthetic VIP) has received Emergency Use Authorization research but is not fully FDA-approved
Updated: 2025-06
PACAP
Endogenous neuropeptide; not an FDA-approved drug product
Updated: 2025-06
Angiotensin 1-7
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Bradykinin
Endogenous peptide used in research; not eligible for compounding
Updated: 2025-06
Atrial Natriuretic Peptide
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
B-type Natriuretic Peptide
Endogenous peptide used in diagnostics; not eligible for compounding
Updated: 2025-06
Endothelin-1
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Apelin
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Adrenomedullin
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Somatostatin
Endogenous peptide; synthetic analogs are FDA-approved instead
Updated: 2025-06
AICAR
Research compound; not eligible for compounding under 503A
Updated: 2025-06
Adamax
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Adipotide
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
PNC-27
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
SLU-PP-332
Research compound; not eligible for compounding under 503A
Updated: 2025-06
Neuroxelin
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Thymalin
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Vilon
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Livagen
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Bronchogen
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Cardiogen
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Pancragen
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Vesilute
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Testagen
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Prostamax
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Chonluten
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
ACE-031
Investigational biologic; not eligible for compounding under 503A
Updated: 2025-06
Tat-Beclin 1
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
B7-33
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Cartalax
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
FGL(S)
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Follistatin-315
Research protein; not eligible for compounding under 503A
Updated: 2025-06
Melanotan I (Afamelanotide)
ShopResearch peptide; afamelanotide (Scenesse) is the FDA-approved analog
Updated: 2025-06
N-Acetyl Epithalon Amidate
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
N-Acetyl Selank Amidate
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
OS-01 (OneSkin Peptide)
Research peptide; not eligible for compounding under 503A
Updated: 2025-06
Ovagen
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
TB-500 Fragment 17-23
Research peptide fragment; not eligible for compounding under 503A
Updated: 2025-06
Thymagen
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Vesugen
Khavinson bioregulator peptide; not eligible for compounding under 503A
Updated: 2025-06
Tesofensine
Small molecule drug, not a peptide. Not eligible for 503A compounding.
PTD-DBM
Not listed on FDA bulk drug substance list for compounding.
GDF-11
Not listed on FDA bulk drug substance list. Research reagent only.
P21
Not listed on FDA bulk drug substance list.
Neuromedin U
Not listed on FDA bulk drug substance list.
Uroguanylin
Not listed on FDA bulk drug substance list. Related approved drugs (linaclotide) exist.
Thymogen
Not listed on FDA bulk drug substance list. No Western regulatory recognition.
Cerluten
Not recognized by FDA. Animal tissue-derived product.
Kristagen
Not recognized by FDA. Animal tissue-derived product.
Astressin-B
Not listed on FDA bulk drug substance list.
Zhenoluten
Not recognized by FDA. Animal tissue-derived product.
Not Applicable
(124)Semaglutide
ShopSemaglutide is an FDA-approved drug (Ozempic, Wegovy, Rybelsus). Compounding is subject to FDA enforcement and ongoing litigation.
Updated: 2025-12-01
Tirzepatide
ShopTirzepatide is an FDA-approved drug (Mounjaro, Zepbound). Compounding subject to FDA enforcement.
Updated: 2025-12-01
PT-141
Bremelanotide (PT-141) is an FDA-approved drug marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Updated: 2025-12-01
Tesamorelin
ShopTesamorelin is an FDA-approved drug marketed as Egrifta/Egrifta SV for HIV-associated lipodystrophy.
Updated: 2025-12-01
Retatrutide
ShopRetatrutide is in clinical trials by Eli Lilly; not available for compounding.
SS-31
SS-31 (elamipretide) is in clinical trials; not available for compounding.
Cerebrolysin
Cerebrolysin is approved in some countries as a pharmaceutical product; not compoundable in the US.
Liraglutide
Liraglutide is FDA-approved as Victoza (diabetes) and Saxenda (obesity).
Cagrilintide
Cagrilintide is in clinical trials by Novo Nordisk.
Survodutide
Survodutide is in clinical trials by Boehringer Ingelheim.
Argireline
Argireline is a cosmetic ingredient, not a drug subject to 503A compounding rules.
ARA-290 (Cibinetide)
ARA-290 (cibinetide) is in clinical trials with FDA Orphan Drug Designation.
Exenatide
FDA-approved branded product (Byetta/Bydureon)
Updated: 2025-06
Dulaglutide
FDA-approved branded product (Trulicity)
Updated: 2025-06
Lixisenatide
FDA-approved branded product (Adlyxin)
Updated: 2025-06
Albiglutide
FDA-approved (Tanzeum); discontinued from market 2018
Updated: 2025-06
Pramlintide
FDA-approved branded product (Symlin)
Updated: 2025-06
Calcitonin (Salmon)
FDA-approved (Miacalcin/Fortical for osteoporosis)
Updated: 2025-06
Setmelanotide
FDA-approved branded product (Imcivree) for rare genetic obesity
Updated: 2025-06
Mazdutide
Investigational dual GLP-1/glucagon receptor agonist; not yet approved
Updated: 2025-06
Pemvidutide
Investigational dual GLP-1/glucagon receptor agonist; not yet approved
Updated: 2025-06
Cotadutide
Investigational dual GLP-1/glucagon receptor agonist; not yet approved
Updated: 2025-06
Danuglipron
Investigational oral GLP-1 receptor agonist (small molecule); not yet approved
Updated: 2025-06
Orforglipron
Investigational oral GLP-1 receptor agonist (small molecule); not yet approved
Updated: 2025-06
Oxytocin
FDA-approved branded product (Pitocin)
Updated: 2025-06
Vasopressin
FDA-approved (Vasostrict) for vasodilatory shock
Updated: 2025-06
Desmopressin
FDA-approved (DDAVP/Stimate) for diabetes insipidus, hemophilia A, nocturnal enuresis
Updated: 2025-06
Terlipressin
FDA-approved (Terlivaz) for hepatorenal syndrome
Updated: 2025-06
Carbetocin
Approved in many countries for PPH prevention; not FDA-approved in US
Updated: 2025-06
Leuprolide
FDA-approved (Lupron, Eligard) for prostate cancer, endometriosis, CPP
Updated: 2025-06
Goserelin
FDA-approved (Zoladex) for prostate cancer, breast cancer, endometriosis
Updated: 2025-06
Triptorelin
FDA-approved (Trelstar) for advanced prostate cancer
Updated: 2025-06
Nafarelin
FDA-approved (Synarel) for endometriosis and CPP
Updated: 2025-06
Histrelin
FDA-approved (Vantas, Supprelin LA) for prostate cancer and CPP
Updated: 2025-06
Degarelix
FDA-approved (Firmagon) for advanced prostate cancer
Updated: 2025-06
Ganirelix
FDA-approved (Ganirelix Acetate Injection) for controlled ovarian stimulation
Updated: 2025-06
Cetrorelix
FDA-approved (Cetrotide) for controlled ovarian stimulation
Updated: 2025-06
Buserelin
Approved in Europe and Canada (Suprefact); not FDA-approved in US
Updated: 2025-06
Macimorelin
FDA-approved diagnostic agent (Macrilen)
Updated: 2025-06
Growth Hormone
FDA-approved biologic (multiple brands); not a compounded product
Updated: 2025-06
IGF-1
FDA-approved biologic (Increlex); not a compounded product
Updated: 2025-06
Collagen Peptides
Dietary supplement; not regulated as a drug
Updated: 2025-06
Matrixyl
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Matrixyl 3000
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Snap-8
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Palmitoyl Tripeptide-1
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Palmitoyl Tetrapeptide-7
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Palmitoyl Tripeptide-5
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Copper Tripeptide-1
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Acetyl Tetrapeptide-5
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Tripeptide-29
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Myristoyl Pentapeptide-17
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Biotinoyl Tripeptide-1
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Oligopeptide-1 / EGF
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Sh-Polypeptide-1
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Angiotensin II
FDA-approved drug (Giapreza); not a compounded product
Updated: 2025-06
Nesiritide
FDA-approved drug (Natrecor); not a compounded product
Updated: 2025-06
Octreotide
FDA-approved drug (Sandostatin); not a compounded product
Updated: 2025-06
Lanreotide
FDA-approved drug (Somatuline Depot); not a compounded product
Updated: 2025-06
Pasireotide
FDA-approved drug (Signifor); not a compounded product
Updated: 2025-06
Glucagon
FDA-approved drug (GlucaGen, Baqsimi); not a compounded product
Updated: 2025-06
Teduglutide
FDA-approved drug (Gattex); not a compounded product
Updated: 2025-06
Plecanatide
FDA-approved drug (Trulance); not a compounded product
Updated: 2025-06
Linaclotide
FDA-approved drug (Linzess); not a compounded product
Updated: 2025-06
Abaloparatide
FDA-approved drug (Tymlos); not a compounded product
Updated: 2025-06
Teriparatide
FDA-approved drug (Forteo); not a compounded product
Updated: 2025-06
Calcitonin Salmon
FDA-approved drug (Miacalcin, Fortical); not a compounded product
Updated: 2025-06
PTH (Parathyroid Hormone)
FDA-approved drug (Natpara); available only through REMS
Updated: 2025-06
Afamelanotide
FDA-approved drug (Scenesse); not a compounded product
Updated: 2025-06
Bremelanotide
FDA-approved drug (Vyleesi); not a compounded product
Updated: 2025-06
Difelikefalin
FDA-approved drug (Korsuva); not a compounded product
Updated: 2025-06
Ziconotide
FDA-approved drug (Prialt); not a compounded product
Updated: 2025-06
Romiplostim
FDA-approved biologic (Nplate); not a compounded product
Updated: 2025-06
Enfuvirtide
FDA-approved drug (Fuzeon); not a compounded product
Updated: 2025-06
Icatibant
FDA-approved drug (Firazyr); not a compounded product
Updated: 2025-06
Eptifibatide
FDA-approved drug (Integrilin); not a compounded product
Updated: 2025-06
Bivalirudin
FDA-approved drug (Angiomax); not a compounded product
Updated: 2025-06
Desirudin
FDA-approved drug (Iprivask); not a compounded product
Updated: 2025-06
HGH 191AA
Identical to FDA-approved recombinant growth hormone; compounding not permitted
Updated: 2025-06
AHK (Ala-His-Lys)
Cosmetic/research peptide; not regulated as a drug
Updated: 2025-06
AHK-Cu (Copper AHK)
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Decapeptide-12
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Melanostatin-DM (Nonapeptide-2)
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Nonapeptide-1
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Pentapeptide-18 (Leuphasyl)
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Rigin (Palmitoyl Tetrapeptide-7)
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
SYN-AKE
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
SYN-COLL (Palmitoyl Tripeptide-5)
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
TRH (Thyrotropin-Releasing Hormone)
FDA-approved diagnostic agent; not a compounded product
Updated: 2025-06
Vialox (Pentapeptide-3)
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Pal-GHK (Palmitoyl Tripeptide-1)
Cosmetic ingredient; not regulated as a drug
Updated: 2025-06
Dermorphin
Eloralintide
Enclomiphene
Follistatin
FOXO4-DRI
GHK
ShopKisspeptin-10
Pal-AHK
Palmitoyl Dipeptide-6
PGPIPN
Somatropin (rHGH)
DS-5
BPC-157 + TB-500
CAGRILINTIDE + SEMAGLUTIDE
Acetyl Tetrapeptide-3
Cosmetic ingredient, not compounded as a drug.
Cholecystokinin (CCK)
Sincalide is an approved diagnostic drug. Not compounded for weight loss.
Peptide YY (PYY)
Endogenous hormone. Not on FDA compounding list.
CGRP
Endogenous peptide. Anti-CGRP drugs are manufactured pharmaceuticals, not compounded.
9-Me-BC
Not a peptide. Research chemical.
Anamorelin
Peptidomimetic small molecule, not a traditional peptide. Approved drug in Japan.
Amycretin
Investigational compound. Not available for compounding.
Cortexin
Animal-derived extract, not a synthetic peptide. Not applicable for 503A compounding.
Ghrelin
GLP-1
Demoxytocin
HMG
Human Relaxin-2
Prostatilen
Retinalamin
CJC-1295 with DAC
ShopBAM-15
Myostatin Propeptide
Trevogrumab
Disclaimer: Regulatory data is compiled from publicly available sources and may not reflect the most recent changes. This page is for educational and research purposes only. Consult official regulatory body websites for authoritative information. All Volta Peptides products are for in vitro research use only.